Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20468142 | 0.89 | GID4 (0.56) | GID4MAPK1MAPK14HAO1SLC6A2 | |
| SCHEMBL5029704 | 0.87 | SLC6A2 (0.57) | GID4SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL8238524 | 0.87 | SLC6A2 (0.57) | GID4SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL29757864 | 0.87 | SLC6A2 (0.57) | GID4SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL4732235 | 0.87 | SLC6A2 (0.57) | GID4SLC6A2SLC6A4SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL5955564 | 0.85 | SLC6A2 (0.56) | GID4MAPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7452684 | 0.83 | GID4 (0.56) | GID4MAPK1MAPK14HAO1SLC6A2 | |
| SCHEMBL7453365 | 0.81 | GID4 (0.64) | GID4MAPK1MAPK14HAO1 | |
| SCHEMBL20863599 | 0.79 | HAO1 (0.53) | GID4MAPK1MAPK14HAO1SLC6A2 | |
| SCHEMBL5709376 | 0.77 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | GID4 3620/4885MAPK1 4265/4885MAPK14 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.